Share Name |
Share Symbol |
Market |
Type |
Share ISIN |
Share Description |
Ekf Diagnostics Holdings Plc |
LSE:EKF |
London |
Ordinary Share |
GB0031509804 |
ORD 1P |
|
Price Change |
% Change |
Share Price |
Bid Price |
Offer Price |
High Price |
Low Price |
Open Price |
Shares Traded |
Last Trade |
|
-1.00 |
-1.3% |
76.00 |
75.50 |
78.00 |
78.00 |
71.00 |
78.00 |
416,167 |
16:46:02 |
Industry Sector |
Turnover (m) |
Profit (m) |
EPS - Basic |
PE Ratio |
Market Cap (m) |
Health Care Equipment & Services |
44.9 |
5.5 |
0.8 |
93.8 |
346 |
Ekf Diagnostics Share Discussion Threads

Showing 2476 to 2500 of 3025 messages
Date | Subject | Author | Discuss |
---|
09/11/2020 13:16 | Yup, fair play Tongosti. Vaccine has certainly helped you there!
Good news for the wider economy. Not good for the share price certainly short term. Early days for the vaccine lots more hurdles to come.
Having a share like this obviously helps when the rest of the world is going down the pan. On a day like today it’ll get a bit of a beating. C’est la vie! |  diviincomesearch | |
09/11/2020 13:13 | Smart - catching a falling knife aren’t you. Hmmm...
PS. Received so much hostility last week bailing out at the very top for +23% profit and warning of impending disaster due to sky high market expectations on the company. Today have added (all cash in bank mind you) another +20% on the way down. What’s better is that I have still have a third of my original short position on now being a free roll. +43% (at trade level - portfolio level contribution at +11%) cash in bank in just a few days is not to be sniffed at chaps. And more likely than not there is still more to come! |  tongosti | |
09/11/2020 13:09 | Don't be mugged-off folks. Just topped-up. Thanks tongosti.. |  sgettings | |
09/11/2020 13:07 | If the vaccine comes to fruition in terms of safety and efficacy, then that can only be a good thing! It could also possibly bring forward EKF's launch of the Kantaro antibody test, especially as there are also questions about how long immunity lasts, and the Kantaro test is currently the only quantitative antibody test available in the market, so it is likely to receive significant demand.
Unfortunately, availability and logistics will mean the vaccine will almost certainly be given to the vulnerable and front line staff initially, so testing of the general population will still be required for quite some time in my view.
Longer term, molecular transport media will be required for continued testing, including differentiating flu from coronavirus, possible mutations (hopefully not!) and country preparedness for future pandemics. |  wan | |
09/11/2020 12:55 | So the price was overextended wasn't it.LOL |  tongosti | |
09/11/2020 12:44 | Wen - any fresh fundamental perspective to share? |  tongosti | |
09/11/2020 12:28 | I have no idea what games are afoot today but I suspect it is people operating on a different timeframe to me. Anyway, I managed to nab some more at 59p which I think will turn out to be good value over my holding period. |  crazycoops | |
09/11/2020 12:25 | Cashed in another batch +17% about a third in open play for some more. Thank you Mr Market. |  tongosti | |
09/11/2020 12:17 | Firsha - any pearls of wisdom from Warren Buffett? |  tongosti | |
09/11/2020 12:15 | To my dear avg Joe:POETIC JUSTICE |  tongosti | |
09/11/2020 12:10 | Yeah, but how many people take it? Here, in the US, it is estimated that 50% of the public intends to take the vaccine. Also, full distribution will take at least 2 quarters. Then there is the likelihood of seasonal strains like flu and the question of durable immunity of past exposure. COVID testing will be safely be in place for 2021 and perhaps well beyond |  jsredbird | |
09/11/2020 12:10 | Between that and Mr Market's judgement I know which one to pick. Cashed in +3% leaving the rest in open play - it's def on the house now. Ah those rookies who filtered me - how they wish they paid attention... |  tongosti | |
09/11/2020 12:07 | Ekf is virus agnostic. Their tubes should be part of the stockpile for future events. I see the income stream lasting for years especially when the inevitable enquiry begins and the benefits are outed. One of the few covid plays that won't be flash in the pan. |  charlieej | |
09/11/2020 12:07 | Bagman - I don't give two hoots about "fullness of time". I trade short term and am +9% up already. Thank you all girls for your valuable "counter-indicator" feedback. That's some trading Wen! |  tongosti | |
09/11/2020 11:57 | Only Mr Market is the Judge of that Joe. Watch this space Einstein.
1. Pfizer vaccine 90% effective. Think about implications (if you can of course)
2. Research you read is provided by corporate cheerleaders (aka storytellers) not people with skin in the game. Clearly, you do not have a clue how the City works.
Good luck - you will need it |  tongosti | |
09/11/2020 11:55 | At the obvious risk of continuing a pointless series of posts I decided a set of scales were needed: on the one side are the Company and research from N+1 Singer and on the other research from the esteemed Tongosti. To me there is a current imbalance but time will tell and until the story works out in real time and is factual maybe best if we stop telling each other what we have done and just carry on quietly. |  welshborderer | |
09/11/2020 11:45 | Brave call Tongosti we will see in the fullness of time Lets see what the implications are with Moonshot we should know in the next 7 days as far as I can see EKF is the only one the Post office can transport but maybe I am missing something
AIMHO
GLA
BTG |  btgman | |
09/11/2020 11:34 | Some rookie a few days back said I must be short. No I wasn't after I cashed my long winnings. Now I have gone short! |  tongosti | |
09/11/2020 11:32 | Worth noting too that they say the antibody test in conjunction with Kantaro to be launched in the new year should provide for further upgrade potential to the 2021 forecasts. |  hastings | |
09/11/2020 11:10 | N+1 Singer:
EKF has confirmed it expects a strong Q4 from both the core business and ongoing demand for the Primestore MTM sample collection device. As a result, FY20 performance is now expected to comfortably exceed market expectations, which have already been upgraded several times through the year. We upgrade our FY20 EBITDA forecasts by a further 6% to £24.4m and look forward to further updates in due course. EKF is a Best Idea for 2020 and we expect strong momentum to continue. |  welshborderer | |
09/11/2020 10:58 | At the risk of ruining the fanclub's parade, the share'd better hold the opening level otherwise it might get quite ugly today. When the news is v bullish and Mr Market doesn't do what the crowd expects that's where v interesting trading opps take place. |  tongosti | |
09/11/2020 09:06 | Odds for a meaningful (at least) major consolidation (or worse!) around existing levels have risen to 93% including last Friday's data. |  tongosti | |
09/11/2020 08:57 | Am sure you have pal but pay attention to how the tape is reacting to it all. |  tongosti | |
09/11/2020 08:57 | It was also a point JB mentioned at the AGM, that he'd rather benefit not just shareholders but also the greater community through EKF investment of spare cash in new health care companies. I presume investment(£5m or $5m?) in Trellus would be classified as intangible asset on the balance sheet, but Verici will now be a tangible asset value. |  faz | |
09/11/2020 08:22 | I have touched on this before.
Looking beyond the financial metrics, how does one value the agreement and relationship with Mount Sinai? This agreement and relationship provides EKF with advanced access to innovative commercial opportunities and presents significant opportunity for EKF to collaborate on ground breaking medical technologies that can be spun off and proceed down the IPO route.
This has already resulted in shareholders benefiting from owning shares via a dividend in-specie in the spin off, Renalytix (£5) and now Verici(50p and in which EKF should have received 2,677,981 shares), and with Trellus Health now firmly in the wings too -
hTTps://trellushealth.com/resources/
If you were only focused on certain financial metrics, then you wouldn't have been invested here to have benefited from what is arguably difficult to measure, but a track record in terms of delivery is very encouraging to say the least! |  wan | |